17年间前列腺癌的临床特征变化

来源期刊：广州医药 | 5-9 发布时间：2021-12-01 收稿时间：2025/11/13 17:21:29 阅读量：26

作者：: 曾维威,

谢克基,

韦兴华,

莫灿程,

汤平,

关键词：: 前列腺癌前列腺癌临床分期前列腺特异性抗原 Gleason评分; Prostate cancer Prostate stage Prostate specific antigen Gleason score

DOI：: 10.3969/j.issn.1000-8535.2018.03.002

收稿时间：: 2018-01-08
修订日期：
接收日期：
引用总数：: 0

目的探讨我院17年间前列腺癌患者的临床特征如发病年龄、前列腺特异性抗原(PSA)、Gleason评分、分期及穿刺阳性率等的变化。方法采用回顾性分析,对广州市第一人民医院2000—2016年泌尿外科1 231例穿刺活检的患者及564例前列腺癌患者资料进行分析,按患者的诊断时间分为A组(2000—2005年)、B组(2006—2009年)、C组(2010—2012年)、D组(2013—2014年)、E组(2015—2016年),对各组的年龄、PSA、Gleason评分、分期及穿刺活检阳性率进行统计学分析,看各组间的各项指标差异是否有统计学意义。结果 5组年龄均值(73.36,73.74,72.05,73.40,72.96岁)、PSA均值(208.95,190.25,173.19,283.54,148.69 μg/L)及穿刺活检阳性率均值(48%,43%,37%,44%,39%)差异均无统计学意义(P均>0.05)。5组Gleason均值为6.80,6.73,7.12,6.93,7.32,A、B组和E组Gleason评分差异有统计学意义(P均<0.05),其余各组Gleason评分差异均无统计学意义(P均>0.05)。TNM分期转化得分5组均值为5.96,6.80,7.05,7.31,6.83, A和C组、D组、E组差异均有统计学意义(P均<0.05),其余各组TNM分期转化得分差异均无统计学意义(P均>0.05)。结论 17年间前列腺癌患者诊断时的年龄、PSA水平及穿刺活检阳性率没有显著变化。

1、 TEISHIMA J, MARUYAMA S, MOCHIZUKI H, et al. Prostate cancer detection by prostate-specific antigen-based screening in the Japanese Hiroshima area shows early stage, low-grade, and low rate of cancer-specific death compared with clinical detection[J]. Can Urol Assoc J, 2014, 8(5-6): E327-332.

2、刘俊,胡卫列,宋波,等. 增加穿刺活检针数提高前列腺癌分级准确性的临床研究[J]. 中华泌尿外科杂志, 2009, 30(10)697-699.

3、 BOKHORST L P, ZHU X, BUL M, et al. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial[J]. BJU Int, 2012, 110(11): 1654-1660.

4、 LOEB S, COOPERBERG M R. Early detection of prostate cancer[J]. Urol Clin North Am, 2014, 41(2): xiii.

5、 JEMAL A, FEDEWA S A, MA J, et al. Prostate cancer incidence and psa testing patterns in relation to USPSTF screening recommendations[J]. JAMA, 2015, 314(19): 2054-2061.

6、 HOFFMAN R M, MEISNER A L, ARAP W, et al. Trends in united states prostate cancer incidence rates by age and stage, 1995-2012[J]. Cancer Epidemiol Biomarkers Prev, 2016, 25(2): 259-263.

7、 WONG M C, GOGGINS W B, WANG H H, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries[J]. Eur Urol, 2016, 70(5): 862-874.

8、那彦群. 中国泌尿外科疾病诊断治疗指南[M]. 北京:人民卫生出版社, 2007: 30-38.

9、 TANG P, CHEN H, UHLMAN M, et al. A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer[J]. Asian J Androl, 2013, 15(1): 129-133.

10、 LIN Y R, WEI X H, UHLMAN M, et al. PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5-10.0 ng ml(-1) and 10.1-20.0 ng ml(-1): a multicenter study[J]. Asian J Androl, 2015, 17(3): 503-507.

11、 TANG P, SUN L, UHLMAN M A, et al. Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men[J]. BJU Int, 2011, 108(1): 44-48.

12、 TANG P, SUN L, UHLMAN M A, et al. Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades duke university experience[J]. Cancer, 2010, 116(20): 4711-4717.

13、叶定伟,朱耀. 中国前列腺癌的流行病学概述和启示[J]. 中华外科杂志, 2015, 53(4): 249-252.

14、 PEYROMAURE M, DEBRE B, MAO K, et al. Management of prostate cancer in China: a multicenter report of 6 institutions[J]. J Urol, 2005, 174(5): 1794-1797.

15、 GAO X, REN S, LU X, et al. The newer the better? Comparison of the 1997 and 2001 partin tables for pathologic stage prediction of prostate cancer in China[J]. Urol, 2008, 72(5): 1096-1101.

16、马春光,叶定伟,李长岭,等. 前列腺癌的流行病学特征及晚期一线内分泌治疗分析[J]. 中华外科杂志, 2008, 46(12): 921-925.

17、 MAIRE A, WILLIAM F, SEAN Altekruse, et al. The Surveillance, Epidemiology, and End Results(SEER)Program and Pathology[J]. Am J Surg pathol, 2016,40(12),e94-102.

18、 SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.

19、 CENTER M M, JEMAL A, LORTET-TIEULENT J, et al. International variation in prostate cancer incidence and mortality rates[J]. Eur Urol, 2012, 61(6): 1079-1092.